Oil prices hold sharp losses with focus on secondary India tariffs
In response to the strong fourth-quarter results and the initiation of full-year 2025 guidance, KeyBanc has released a revised model for Repligen (NASDAQ:RGEN). The update reflects the company’s recent performance and its outlook for the coming year, reinforcing the analyst’s confidence in the stock’s potential for double-digit growth in 2025. The stock has shown remarkable momentum with a 10.72% return over the past week and a 13.01% gain year-to-date. For deeper insights into Repligen’s valuation and growth prospects, including exclusive ProTips and comprehensive financial analysis, check out the detailed Pro Research Report available on InvestingPro. The stock has shown remarkable momentum with a 10.72% return over the past week and a 13.01% gain year-to-date. For deeper insights into Repligen’s valuation and growth prospects, including exclusive ProTips and comprehensive financial analysis, check out the detailed Pro Research Report available on InvestingPro.
In response to the strong fourth-quarter results and the initiation of full-year 2025 guidance, KeyBanc has released a revised model for Repligen. The update reflects the company’s recent performance and its outlook for the coming year, reinforcing the analyst’s confidence in the stock’s potential for double-digit growth in 2025. The stock has shown remarkable momentum with a 10.72% return over the past week and a 13.01% gain year-to-date. For deeper insights into Repligen’s valuation and growth prospects, including exclusive ProTips and comprehensive financial analysis, check out the detailed Pro Research Report available on InvestingPro.
The analyst’s comments also suggest that Repligen’s results serve as a leading indicator for other companies in the sector that provide filters, additives, and equipment, including Danaher Corporation (NYSE:DHR), Avantor, Inc. (NYSE:AVTR), Thermo Fisher Scientific Inc. (NYSE:TMO), and Sartorius AG (FRA:ETR:SATG). The positive outlook is further supported by the company’s sixth consecutive quarter of book-to-bill ratio over 1.0x and increasing orders for Contract Development and Manufacturing Organizations (CDMOs) and capital equipment, which have risen 15% and 30% sequentially, respectively.
In response to the strong fourth-quarter results and the initiation of full-year 2025 guidance, KeyBanc has released a revised model for Repligen. The update reflects the company’s recent performance and its outlook for the coming year, reinforcing the analyst’s confidence in the stock’s potential for double-digit growth in 2025.
In other recent news, Repligen Corporation reported its fourth-quarter earnings, surpassing analyst expectations with an earnings per share (EPS) of $0.44, compared to the forecasted $0.41. The company’s revenue also exceeded projections, coming in at $168 million against an expected $167.67 million. Repligen has provided an optimistic forecast for fiscal year 2025, with anticipated EPS between $1.67 and $1.76, and revenue projections ranging from $685 million to $710 million. Jefferies has raised its price target for Repligen to $165, maintaining a Hold rating, acknowledging the company’s strong fourth-quarter results and positive 2025 guidance.
The company has also announced the launch of new products, including single-use mixers, which are expected to contribute to its growth. Repligen’s recent acquisition of Tantti Laboratory Inc. and the introduction of innovative products like the AVIPure® dsRNA resin are seen as strategic moves to enhance its market position. Jefferies analyst Matthew Stanton noted the company’s focus on differentiated growth drivers and the potential for an upside to financial forecasts. Repligen’s strategic initiatives and financial guidance indicate a promising outlook for 2025, with the company expecting stronger performance in the latter half of the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.